San Diego Biotechnology Network: Biotech Events, Jobs, News, Companies, Directory, Blog, & Calendar » Syndication

Scientist Senior - 22848 – Genzyme – San Diego, CA

jobs — Sat, 31 Jul 2010 02:49:17 +0000

Description Genzyme Corporation, ranked as one of the foremost biotechnology companies in the world, is committed to providing an exceptional environment in...
From Genzyme - 31 Jul 2010 02:49:17 GMT - job details - View all San Diego jobs

Senior Shipper/Receiver – Vertex – San Diego, CA

jobs — Fri, 30 Jul 2010 23:24:53 +0000

Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for...
From Vertex - 30 Jul 2010 23:24:53 GMT - job details - View all San Diego jobs

Senior Buyer – Vertex – San Diego, CA

jobs — Fri, 30 Jul 2010 23:24:06 +0000

Connect Adopts New Measures to Boost the Innovation Economy

Mary Canady — Fri, 30 Jul 2010 11:40:06 +0000

Connect, the San Diego nonprofit group for technology and entrepreneurship, said its board has approved a series of initiatives intended to stimulate the long-term formation of technology startups....

[[Click headline to continue reading.]]

Research Associate/Sr. Research Associate, Purification Development – Pfizer – San Diego, CA

jobs — Fri, 30 Jul 2010 06:59:00 +0000

dependents the variety and flexibility to help address their needs at different stages in life. Company Profile: CovX is a biotechnology unit within Pfizer
From HealthcareJobsite.com - 30 Jul 2010 06:59:00 GMT - job details - View all San Diego jobs

Research Associate/Sr. Research Associate, Analytical – Pfizer – San Diego, CA

jobs — Fri, 30 Jul 2010 06:59:00 +0000

Orexigen Therapeutics, Inc. Announces Publication of COR-I Phase 3 Study of Contrave in Lancet

BioSpace.com Featured News — Fri, 30 Jul 2010 00:00:00 +0000

SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) announced that results from its COR-I trial of Contrave were published online today in the journal Lancet. COR-I was the largest of the four, 56-week, Phase 3 trials supporting the New Drug Application for Contrave, currently under review by the U.S. Food and Drug Administration...

Cadence Pharmaceuticals, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2010 Financial Results on August 5, 2010

BioSpace.com Featured News — Fri, 30 Jul 2010 00:00:00 +0000

SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its second quarter ended June 30, 2010 financial...

Gen-Probe Incorporated Reports Financial Results for the Second Quarter of 2010

BioSpace.com Featured News — Fri, 30 Jul 2010 00:00:00 +0000

SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) today reported financial results for the second quarter of 2010, highlighted by 14% growth in product sales, 15% growth in total revenues, and 16% growth in non-GAAP earnings per share (EPS).

"Gen-Probe's second quarter financial results demonstrate our ability to drive growth...

Genoptix, Inc. Reports Operating Results for the Second Quarter 2010

BioSpace.com Featured News — Fri, 30 Jul 2010 00:00:00 +0000

CARLSBAD, Calif., July 29 /PRNewswire-FirstCall/ -- Genoptix, Inc. (Nasdaq: GXDX), a specialized laboratory services provider, today reported revenue of $50.9 million for the second quarter of 2010. Net income was $5.6 million or $0.31 per diluted share for the quarter. ...